Despite breakthrough treatments for high-grade serous ovarian cancer, about 80 percent of patients relapse within two years, often resistant to treatment. The good news is that Dana-Farber scientists are pursuing multiple avenues of research that very well may improve outcomes. “A number of patients develop progressive disease at a later point, potentially indicating that a … Read more
The time may not be far off when the treatment for a person’s ovarian cancer can be tailored to their malignancy using drugs selected by testing on “organoids” — miniature 3-D clusters of cancer cells grown from a patient’s own tumor cells. Although ovarian organoid tests are not yet being used to guide treatment decisions, … Read more
Studies in the lab of Cigall Kadoch, PhD, are shedding new light on how molecular machines called BAF chromatin remodeling complexes “go where they need to go” within the DNA genome of cells, binding to specific locations to govern which genes turn on and off to orchestrate cell functions. The findings, described in the journal … Read more
The majority of women diagnosed with breast cancer have early-stage disease that is confined to the breast or nearby lymph nodes and is effectively treated by lumpectomy or mastectomy. Nevertheless, small clusters of cancer cells remaining after surgery — called micrometastases — have the potential to spread at some point and cause a cancer recurrence, … Read more
Many cancers develop from cells that have a malfunctioning tumor suppressor gene, p53, which normally helps control unchecked cell growth and prevent cancer. Some scientists are pursuing a strategy of restoring p53 gene function in cancer cells to stop their unruly growth or kill them. The exact effects of reviving p53 activity in tumors are … Read more
Scientists are beginning to make inroads into treating cholangiocarcinoma, a rare, lethal cancer of the bile ducts, with precision drugs. Last year, the first targeted drug for some patients with the disease was approved. Now, Dana-Farber scientists say they have identified another genetic alteration in a small percentage of cholangiocarcinoma patients that can be attacked … Read more
Tumors are scrupulous recorders of their own life stories. The wreckage they acquire as a result of therapy, the stratagems they use to survive and dodge an immune attack are all inscribed in their DNA and the set of immune system cells within them. Unfortunately for science, the autobiography of a tumor rarely consists of … Read more
A protein that normally serves useful functions in the body like helping wounds heal and repairing damaged tissues is also high on scientists’ “most wanted” list of cancer culprits. Called STAT3, the protein has been found to be overactive in a variety of cancers — including breast cancer — driving malignant growth, survival, and metastasis. … Read more
Cancer cells have a bias toward survival, often becoming heavily reliant on certain protein pathways to sustain themselves. Scientists are finding ways to turn that survival instinct into a liability — by making the cells even more dependent on those pathways, then choking the pathways off. It’s an approach that has now yielded a promising … Read more
Cancer drugs like Gleevec or Herceptin, which were approved for us in the 1990s, prompted hopes of transforming cancer care and perhaps render harsh treatments like chemotherapy obsolete. Known as precision or targeted therapies, these drugs are designed to block the action of specific mutated genes or proteins that drive malignant tumor growth, while sparing … Read more
For an estimated 10% to 30% of people who survive acute COVID-19 illness, the road to full recovery is lengthy and plagued with an array of persistent ills ranging from “brain fog” to fatigue, shortness of breath, gastrointestinal distress, impaired sense of smell, and neurological symptoms. Doctors call this syndrome, “long COVID or post-acute COVID-19,” … Read more
New treatment approaches have increased the number of older patients with myelodysplastic syndromes (MDS) eligible for a stem cell transplant. Now, Dana-Farber research has identified those that are most likely to benefit from one. In a prospective study involving patients age 60 to 75 with advanced MDS, investigators found that participants at high risk of … Read more
Despite the sometimes-dramatic success of new cancer immunotherapies like checkpoint inhibitor drugs and CAR T cells, thus far only a minority of patients have responded or gained long-lasting benefits. A major reason for the inconsistent results of immunotherapy is a phenomenon known as “T-cell exhaustion” — a weakening or loss of tumor-killing function by T … Read more
Immune therapies declare open season on cancer, rousing immune system cells to take up an attack on tumors. But which immune cells join the hunt, which sit it out, and what happens within immune cells that causes them to go on the offensive? Such questions are especially relevant when immunotherapies show only limited effectiveness against … Read more
Thanks to developments in precision medicine, some adult cancers are now treated with designer drugs that target the genetic mutations that caused them. But most children with cancer have not reaped the same benefits. Unlike adult cancers, childhood cancers carry few genetic mutations. And the mutations these tumors do have are typically harder to make … Read more
Having come to fame as the basis of the Moderna and Pfizer/BioNTech vaccines for COVID-19, messenger RNA — or mRNA — is in many ways the molecule of the moment. Its newfound prominence is also raising its profile as a powerful tool in cancer research. Scientists are using it learn how cancer cells sometimes disarm … Read more
A form of immune cell therapy for cancer known as tumor infiltrating lymphocyte, or TIL, therapy, involves removing immune T cells from a piece of the patient’s tumor — where the T cells have succeeded in recognizing the cancer — expanding them outside the body, and re-infusing them by the billions to fight the disease. … Read more
Discovering new cancer treatment can sometimes be a matter of connecting the dots between new pathways and old drugs. That was the case in a new paper in the TKTK issue of Clinical Cancer Research co-authored by Kent Mouw MD, PhD, co-director of Dana-Farber’s Bladder Cancer Center. Mouw and his team found a promising way … Read more
Infection with the Epstein-Barr virus (EBV) is a rite of passage for most of humanity. More than 90 percent of all people on earth contract the virus — most in early childhood — with no ill consequences, because the immune system keeps it under control. When the immune response is dampened by immunosuppressive drugs or … Read more
A new “deep learning” form of artificial intelligence outperformed standard methods in identifying cancer patients with inherited DNA alterations that could increase their risk of developing cancer or improve their response to certain targeted cancer drugs. Dana-Farber researchers led by Saud H. AlDubayan, MD, and Eliezer Van Allen, MD, report in JAMA that the analytical … Read more